Pharmacokinetics of oral doxifluridine in patients with colorectal cancer

Tumori

Volumn 85, Issue 1, 1999, Pages 47-50

  Zampino, Maria Giulia ^a,b   Colleoni, Marco ^a,b   Bajetta, Emilio ^a   Stampino, Corrado Gallo ^a,c   Guenzi, Alberto ^a,c   De Braud, Filippo ^a,b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c ROCHE MILANO RICERCHE   (Italy)

Author keywords

Doxifluridine; Oral chemotherapy; Pharmacokinetics

Indexed keywords

DOXIFLURIDINE; FLUOROURACIL; FOLINIC ACID;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; HUMAN; MUCOSA INFLAMMATION; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRACTICE GUIDELINE; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; STOMACH PAIN;

EID: 0032968114     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089169908500110     Document Type: Article

References (19)

1. Abele R., Alberto P., Kaplan S., Siegenthaler P., Hofman V., Russell H.J., Hartmann D., Holdener F.E., Cavalli F.: Phase II study of doxifluridine in advanced colorectal adenocarcinoma. J. Clin. Oncol., 12: 750-754, 1983.
2. Alberto P., Mermillod B., Germano G., Kaplan S., Weber W., Joss R., Spati B., Martz G., Cavalli F.: Randomized comparison of doxifluridine and fluorouracil in colorectal carcinoma. Eur. J. Cancer Clin. Oncol., 24: 559-563, 1988.
3. Alberto P., Winkelmann J.J., Paschoud N., Peytremann R., Bruyere A., Decoster G., Holdener F.E.: Phase I study of oral doxifluridine using two schedules. Eur. J. Cancer, 25: 905-908, 1989.
4. Armstrong R.D., Cadman E.: 5'-deoxy-5-fluorouridine selective toxicity for human tumor cells compared to human bone marrow. Cancer Res., 43: 2525-2528, 1983.
5. Armstrong R.D., Diasio R.B.: Metabolism and biological activity of 5-deoxy-5-fluorouridine, a novel fluoropyrimidine. Cancer Res., 40: 3333-3338, 1980.
6. Au J.L.-S., Walker J.S., Rustum Y.: Pharmacokinetic studies of 5-fluorouracil and 5'-deoxy-5-fluorouridine in rats. J. Pharmacol. Exp. Ther., 1: 174-180, 1983.
7. Bajetta E., Colleoni M., Di Bartolomeo M., Buzzoni R., Bozzetti F., Doci R., Somma L., Cappuzzo F., Stampino C.G., Guenzi A.: Doxifluridine and leucovorin: an oral treatment combination in advanced colorectal cancer. J. Clin. Oncol., 13: 2613-2619, 1995.
8. Bollag W., Hartmann H.R.: Tumor inhibitory effects of a new fluorouracil derivative: 5-deoxy-5-fluorouridine. Eur. J. Cancer, 16: 427-432, 1979.
9. Cook A.F., Holman M.J., Kramer M.J., Trown P.W.: Fluorinated pyrimidine nucleosides: three syntheses and antitumor activity of a series of 5-deoxy-5-fluoropyrimidine nucleosides. J. Med. Chem., 22: 1330-1335, 1979.
10. Fossa S.D., Dahl O., Hoel R.: Doxifluridine (5'dFUR) in patients with advanced colorectal carcinoma. Cancer Chemother. Pharmacol., 15: 161-163, 1985.
11. Guentert T.W., Heintz R.C., Pettavel J., Germano G.: Influence of dose and route of administration on the pharmacokinetics of doxifluridine and its metabolite fluorouracil. Chemioterapia, 4: 1167-1169, 1984.
12. Heintz R.C., Guentert T.W., Sutter C.: Pharmacokinetic profile of doxifluridine (5'dFUR, Furtulon) a 5-fluorouracil (5-FU) pro-drug (Abst.). Proc. Am. Assoc. Cancer Res., 27: 207, 1986.
13. Hurteloup P., Armand J.P., Cappelaere P., Mrtz R., Kerbrat P., Keiling R., Fumoleau P., Fargeot P., Schraub S., Batist P.: Phase II clinical evaluation of doxifluridine. Cancer Treat. Rep., 70: 731-737, 1986.
14. Ishitsuka H., Miwa M., Takemoto K., Fukuoka K., Itoga A., Maruyama H.B.: Role of uridine phosphorylase for antitumor activity of 5'-deoxy-5-fluorouridine. Gann, 71: 112-123, 1980.
15. Kimura K., Saito T., Taguchi T.: Experimental and clinical studies on the anticancer agent doxifluridine (5'-dFUR). J. Int. Med. Res., 16: 1-37, 1988.
16. Ota K.: Multicentre cooperative phase II study of 5-deoxy-5-fluorouridine in the treatment of colorectal cancer. J. Int. Med. Res., 16: 19-20, 1988.
17. Suzuki S., Hongu Y., Fukazawa H., Hichihara S., Shimizu H: Tissue distribution of 5'-deoxy-5-fluorouridine and derived 5-fluorouracil in tumor-bearing mice and rats. Gann, 71: 238-245, 1980.
18. Trave F., Cannobbio L., Au J.L., Rustum Y.M.: Role of administration route in the therapeutic efficacy of doxifluridine. J. Natl. Cancer Inst., 78: 527-532, 1987.
19. Yoshimori K., Hasegawa K.: Study on efficacy and safety of 5'-deoxy-5-fluorouridine (5'-dDFUR) with intermittent administration. Progr. Antimicrob. Anticancer Chemother., 3: 493-495, 1987.